MENU
+Compare
RYTM
Stock ticker: NASDAQ
AS OF
Jul 29 closing price
Price
$85.63
Change
-$0.05 (-0.06%)
Capitalization
5.65B

RYTM Rhythm Pharmaceuticals Forecast, Technical & Fundamental Analysis

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company... Show more

Industry: #Biotechnology
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for RYTM with price predictions
Jul 29, 2025

RYTM in upward trend: 10-day moving average broke above 50-day moving average on July 01, 2025

The 10-day moving average for RYTM crossed bullishly above the 50-day moving average on July 01, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

RYTM moved above its 50-day moving average on June 27, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RYTM advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 221 cases where RYTM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for RYTM moved out of overbought territory on July 24, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 23, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RYTM as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RYTM turned negative on July 25, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RYTM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RYTM broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RYTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RYTM's P/B Ratio (294.118) is very high in comparison to the industry average of (18.138). P/E Ratio (0.000) is within average values for comparable stocks, (60.154). RYTM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.604). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (38.610) is also within normal values, averaging (278.954).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
RYTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

RYTM is expected to report earnings to fall 17.27% to -67 cents per share on August 05

Rhythm Pharmaceuticals RYTM Stock Earnings Reports
Q2'25
Est.
$-0.67
Q1'25
Missed
by $0.14
Q4'24
Beat
by $0.02
Q3'24
Beat
by $0.07
Q2'24
Beat
by $0.16
The last earnings report on May 07 showed earnings per share of -81 cents, missing the estimate of -67 cents. With 418.88K shares outstanding, the current market capitalization sits at 5.65B.
A.I. Advisor
published General Information

General Information

a developer of peptide therapeutics for metabolic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
222 Berkeley Street
Phone
+1 857 264-4280
Employees
226
Web
http://www.rhythmtx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WIESX17.840.08
+0.45%
Wasatch Emerging Markets Select Instl
JLCAX21.61N/A
N/A
JPMorgan US Large Cap Core Plus A
VLISX611.19N/A
N/A
Vanguard Large Cap Index Institutional
ESIFX12.56N/A
N/A
Eaton Vance Balanced R6
TSAMX14.16N/A
N/A
Thornburg Summit A

RYTM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with CRNX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
N/A
CRNX - RYTM
45%
Loosely correlated
-3.50%
VRNA - RYTM
45%
Loosely correlated
+0.08%
IDYA - RYTM
43%
Loosely correlated
-0.72%
RVMD - RYTM
42%
Loosely correlated
-0.67%
DNLI - RYTM
42%
Loosely correlated
-0.07%
More